The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 29, 2023

Filed:

May. 11, 2021
Applicant:

Eirgen Pharma Ltd., Waterford, IE;

Inventors:

P. Martin Petkovich, Kingston, CA;

Joel Z. Melnick, Evanston, IL (US);

Jay A. White, Newmarket, CA;

Samir P. Tabash, Whitby, CA;

Charles W. Bishop, Miami, FL (US);

Susan Peers, Toronto, CA;

Stephen A. Strugnell, Madison, WI (US);

Assignee:

EIRGEN PHARMA LTD., Waterford, IE;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/593 (2006.01); A61K 31/592 (2006.01); A61K 9/00 (2006.01); A61K 47/26 (2006.01); A61K 9/48 (2006.01); A61K 31/675 (2006.01); A61K 39/395 (2006.01); A61K 31/135 (2006.01); A61K 31/663 (2006.01); A61K 47/44 (2017.01); A61K 31/137 (2006.01); A61K 45/06 (2006.01); A61K 47/06 (2006.01); A61K 47/14 (2017.01); A61K 47/38 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/593 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/4825 (2013.01); A61K 9/4875 (2013.01); A61K 31/135 (2013.01); A61K 31/137 (2013.01); A61K 31/592 (2013.01); A61K 31/663 (2013.01); A61K 31/675 (2013.01); A61K 39/395 (2013.01); A61K 45/06 (2013.01); A61K 47/06 (2013.01); A61K 47/14 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01); A61K 47/44 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/76 (2013.01);
Abstract

Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.


Find Patent Forward Citations

Loading…